By unveiling a novel mechanism connecting the DDR, cell cycle checkpoints, and PTEN, a key tumor suppressor that is often disrupted in cancers, our study has therapeutic implications for the clinical development of a number of new anticancer drugs that target various cell cycle regulators. The gene discussed is PTEN; the disease is cancer.